Tanja Eisemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tanja Eisemann has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Robert J. Wechsler-Reya
Cancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
30 shared publications - Abbey Rocco
Division of Pediatric Hematology and Oncology, Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama. 1
27 shared publications - Elizabeth A. Beierle
Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
27 shared publications - G. Yancey Gillespie
10Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama
27 shared publications - Gregory K. Friedman
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications - James M. Markert
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
27 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (38)
Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing
Medulloblastomas are considered immunologically cold and refractory to immunotherapy. One factor contributing to their low immunogenicity is impaired antigen presentation, which allows tumor cells to evade cytotoxic T cells. Using a syngeneic mouse model of medulloblastoma, we demonstrate that despite low expression of MHC class I on tumor cells, depletion of CD8 + T cells accelerates tumor growth, whereas adoptive transfer of tumor-reactive CD8 + T cells prolongs survival. These antitumor effects rely on T cell–derived interferon gamma (IFNγ), which induces MHC class I on tumor cells and facilitates tumor cell killing by T cells. Importantly, delivering IFNγ directly into tumors via convection-enhanced delivery enhances CD8 + T cell–mediated killing of tumor cells and significantly prolongs survival in tumor-bearing mice. These studies highlight the importance of T cells in controlling brain tumors and the value of IFNγ as an adjuvant for T cell–based immunotherapy.
- 14 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (38)
Open AccessLocal delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing
Medulloblastomas are considered immunologically cold and refractory to immunotherapy. One factor contributing to their low immunogenicity is impaired antigen presentation, which allows tumor cells to evade cytotoxic T cells. Using a syngeneic mouse model of medulloblastoma, we demonstrate that despite low expression of MHC class I on tumor cells, depletion of CD8 + T cells accelerates tumor growth, whereas adoptive transfer of tumor-reactive CD8 + T cells prolongs survival. These antitumor effects rely on T cell–derived interferon gamma (IFNγ), which induces MHC class I on tumor cells and facilitates tumor cell killing by T cells. Importantly, delivering IFNγ directly into tumors via convection-enhanced delivery enhances CD8 + T cell–mediated killing of tumor cells and significantly prolongs survival in tumor-bearing mice. These studies highlight the importance of T cells in controlling brain tumors and the value of IFNγ as an adjuvant for T cell–based immunotherapy.
- Open Access
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
CD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessCD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.